Anticholinergics for symptomatic management of Parkinson's disease.
about
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersStriatal cholinergic interneuron regulation and circuit effectsThe differential diagnosis and treatment of tremorLong-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections.Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease.Pharmacotherapy in Parkinson's disease: case studies.Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian micePriority setting partnership to identify the top 10 research priorities for the management of Parkinson's diseasePresent and future drug treatment for Parkinson's disease.Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4)Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditionsEffective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns.Hydroxycinnamic acid amides from Scopolia tangutica inhibit the activity of M1 muscarinic acetylcholine receptor in vitro.Parkinson's disease between internal medicine and neurologyAlternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures.Striatal cholinergic interneurons generate beta and gamma oscillations in the corticostriatal circuit and produce motor deficits.Effect of Anticholinergic Medications on Falls, Fracture Risk, and Bone Mineral Density Over a 10-Year Period.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's locationTrends in antiparkinsonian medication use in new zealand: 1995-2011.Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.Non-human primate models of PD to test novel therapies.Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.Drugs for Parkinson’s disease: levodopa is still the gold standard.Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors.Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.The nature of postural tremor in Parkinson disease.Patterns and Predictors of Depression Treatment among Older Adults with Parkinson's Disease and Depression in Ambulatory Care Settings in the United States.The striatal cholinergic system in L-dopa-induced dyskinesias.[Pharmacological treatment of motor symptoms in Parkinson's diseases].Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor.Analysis of spatiotemporal pattern and quantification of gastrointestinal slow waves caused by anticholinergic drugs.Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review.Transitioning from Unilateral to Bilateral Upper Limb Tremor Therapy for Parkinson's Disease and Essential Tremor Using Botulinum Toxin: Case SeriesStriatal input- and rate-dependent effects of muscarinic receptors on pallidal firingSugar Addiction: From Evolution to Revolution
P2860
Q24605472-39509EA9-0868-40ED-8801-E55693D76C8FQ26863113-338BE5E6-56A0-4023-B4F5-9B01AF3F629FQ27010102-612E0B6D-BC9C-4430-8487-1DFFED65D8E3Q33769128-55FD732E-1452-49C9-B379-DA12A7880F2BQ33917311-CB358812-2F07-45AD-8476-4B25B0020D6BQ34409459-E7AF36DB-159D-4F4B-81C8-2BDBD6A9CEB4Q34490801-6497E4E6-871E-47F3-A26D-F9395EEC63A8Q34799941-84182BAA-1E70-4BAA-9D73-9D718AD2251DQ35484805-C776AA04-B046-40E1-93C4-F41125EE729CQ35602706-4316C058-140E-4ECC-A78D-D22BFDB9167BQ35776844-0602D2A6-ED19-4430-B275-63F925DD5972Q36042479-DB0F2FD0-5BBC-45A6-A8C9-C3FA2F2DBDC1Q36256873-59838CC5-3E09-4102-9FA7-6F84176D3276Q36421337-4FEB59DD-F408-4FF0-A562-9B948FC9D6AFQ36464243-6693879D-A167-4DD3-8FE8-77815B231350Q36961194-31D907BE-DF9E-4FD5-BCAC-ABE603FAB511Q36978058-5FB859CE-C7C2-4A81-95CF-039954EDFE81Q37452317-749B104C-0D3F-4C2D-84C1-550677877FADQ37512670-1C33D79B-D0FE-456B-B8BE-ED4AC0727B43Q37591499-FB1B1AC4-694F-4847-BD07-D58F7102A770Q37603769-308973D4-7AF6-445D-81EE-746D08A0813DQ37651160-7CDB2FDD-18FB-4171-8080-76F799598921Q38609231-49B5E374-C310-47BD-AD46-DAF808131A3BQ39229450-A5B21DF6-0083-465F-9FA4-DB28B8482351Q39789571-BAEC85D7-CD4E-40F2-A9A4-21063DA9F9E2Q42392688-2EEBB205-9609-428D-A46E-AE97037F75DEQ42392773-43A57D39-FAFE-4F9B-A0A8-27AB47E8C165Q42971243-B9E5A9D4-C94E-4215-B720-5766F3009063Q45873810-66D0304E-0B18-4A1F-93CC-1A36CD8FDA87Q50238794-2F36FE48-103B-44B7-846C-2D1E41FC4A04Q52311656-D1DD2475-7F2C-48E0-8ADA-A0058ADAA8D7Q52680310-DA7B50F8-5101-4CE6-8D3F-1775F5CA4DC5Q52703430-CAFF6634-E37A-498F-9C2C-574DEAE1493CQ52740407-9137BB2B-A44D-4DBB-A5F7-ACD9CACB8B6CQ54982279-7F379DEE-F81A-4076-9E2B-095175CB24C7Q55069615-A92C0CD0-5CB7-47F7-8C36-575F396E8899Q58698299-1D42A09D-93DD-4612-B2ED-7AB36B37D7ABQ58914830-0FB77EA4-3E58-4B23-BA70-93B75929A69EQ59134991-1D136DB8-068F-41D6-9D87-4D2EF1C46531
P2860
Anticholinergics for symptomatic management of Parkinson's disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Anticholinergics for symptomatic management of Parkinson's disease.
@ast
Anticholinergics for symptomatic management of Parkinson's disease.
@en
Anticholinergics for symptomatic management of Parkinson's disease.
@nl
type
label
Anticholinergics for symptomatic management of Parkinson's disease.
@ast
Anticholinergics for symptomatic management of Parkinson's disease.
@en
Anticholinergics for symptomatic management of Parkinson's disease.
@nl
prefLabel
Anticholinergics for symptomatic management of Parkinson's disease.
@ast
Anticholinergics for symptomatic management of Parkinson's disease.
@en
Anticholinergics for symptomatic management of Parkinson's disease.
@nl
P2093
P2860
P1476
Anticholinergics for symptomatic management of Parkinson's disease.
@en
P2093
R Katzenschlager
P2860
P304
P356
10.1002/14651858.CD003735
P577
2003-01-01T00:00:00Z